Skip to content

South Africa’s lop-sided TB response: more attention to prevention of drug resistance required

The scale of the challenge in fight against TB in South Africa

Superinfection seen frequently in heterosexual couples in Zambia

Once-daily darunavir/ritonavir may be an option for some treatment-experienced patients

Darunavir European license extended to all treatment-experienced

Tenofovir/FTC more effective than abacavir/3TC in first-line boosted-PI regimens: meta-analysis

Initial CD4 cell counts in new seroconverters have declined over time

Raltegravir resistance patterns becoming clearer

Vicriviroc: long-term safety concerns over cancers dispelled